FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

MM de Boer-Dennert

Research Profile

Chemicals & Drugs

Concepts & Ideas

Procedures

Disorders

Phenomena

Metabolic Clearance Rate

Co-author Network

Publications

TOP 3
A S T Planting; Pieter Sonneveld; Ate van der Gaast; Alex Sparreboom; M E L van der Burg; G P M Luyten; K de Leeuw; MM de Boer-Dennert; Paul Wissel; Roxanne C Jewell; Elaine M Paul; N B Purvis; Jaap Verweij
A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
J H M Schellens; A S T Planting; nico van zandwijk; J Ma; Marc Maliepaard; M E L van der Burg; MM de Boer-Dennert; E Brouwer; Ate van der Gaast; Martin J van den Bent; Jaap Verweij
Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer.
J H M Schellens; A S T Planting; J Ma; Marc Maliepaard; A de Vos; MM de Boer-Dennert; Jaap Verweij
Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of MM de Boer-Dennert (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2005: A S T Planting; Pieter Sonneveld; Ate van der Gaast; Alex Sparreboom; M E L van der Burg; G P M Luyten; K de Leeuw; MM de Boer-Dennert; Paul Wissel; Roxanne C Jewell; Elaine M Paul; N B Purvis; Jaap Verweij
A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2005;55(1):91-9.
2003: J H M Schellens; A S T Planting; nico van zandwijk; J Ma; Marc Maliepaard; M E L van der Burg; MM de Boer-Dennert; E Brouwer; Ate van der Gaast; Martin J van den Bent; Jaap Verweij
Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer.
British journal of cancer 2003;88(6):814-21.
2001: J H M Schellens; A S T Planting; J Ma; Marc Maliepaard; A de Vos; MM de Boer-Dennert; Jaap Verweij
Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer.
Anti-cancer drugs 2001;12(8):667-75.
2000: M J A de Jonge; Jaap Verweij; Peter de Bruijn; E Brouwer; Ron H J Mathijssen; RJ van Alphen; MM de Boer-Dennert; Laurent Vernillet; Christian Jacques; Alex Sparreboom
Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):195-203.
2000: M J A de Jonge; Alex Sparreboom; A S T Planting; M E L van der Burg; MM de Boer-Dennert; Judith ter Steeg; Christian Jacques; Jaap Verweij
Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):187-94.
1999: A S T Planting; J H M Schellens; M E L van der Burg; MM de Boer-Dennert; B Winograd; Gerrit Stoter; Jaap Verweij
Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors.
Anti-cancer drugs 1999;10(9):821-7.
1999: M J A de Jonge; Jaap Verweij; A S T Planting; M E L van der Burg; Gerrit Stoter; MM de Boer-Dennert; Peter de Bruijn; E Brouwer; Laurent Vernillet; Alex Sparreboom
Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(8):2012-7.
1999: Lia van Zuylen; J H M Schellens; Swan Hoo Goey; LC Pronk; MM de Boer-Dennert; Walter J Loos; J Ma; Gerrit Stoter; Jaap Verweij
Phase I and pharmacologic study of the arotinoid Ro 40-8757 in combination with cisplatin and etoposide in patients with non-small cell lung cancer.
Anti-cancer drugs 1999;10(4):361-8.
1999: LC Pronk; Wim L J van Putten; V van Beurden; MM de Boer-Dennert; Gerrit Stoter; Jaap Verweij
The venotonic drug hydroxyethylrutosiden does not prevent or reduce docetaxel-induced fluid retention: results of a comparative study.
Cancer chemotherapy and pharmacology 1999;43(2):173-7.
1997: LC Pronk; J H M Schellens; A S T Planting; Martin J van den Bent; P H E Hilkens; M E L van der Burg; MM de Boer-Dennert; J Ma; C Blanc; M Harteveld; R Bruno; Gerrit Stoter; Jaap Verweij
Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(3):1071-9.
1997: MM de Boer-Dennert; Ronald de Wit; P I M Schmitz; J Djontono; V v Beurden; Gerrit Stoter; Jaap Verweij
Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists.
British journal of cancer 1997;76(8):1055-61.
1997: C J H Gerrits; J H M Schellens; Geert-Jan Creemers; Paul Wissel; A S T Planting; J F Pritchard; S DePee; MM de Boer-Dennert; M Harteveld; Jaap Verweij
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.
British journal of cancer 1997;76(7):946-51.
1997: A S T Planting; S Kho; M E L van der Burg; H Goey; J H M Schellens; Martin J van den Bent; Ate van der Gaast; MM de Boer-Dennert; Gerrit Stoter; Jaap Verweij
A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer.
Cancer chemotherapy and pharmacology 1997;40(4):347-52.
1996: A S T Planting; M E L van der Burg; Swan Hoo Goey; J H M Schellens; C Vecht; MM de Boer-Dennert; Gerrit Stoter; Jaap Verweij
Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic malignant melanoma.
European journal of cancer (Oxford, England : 1990) 1996;32A(11):2026-8.
1996: Geert-Jan Creemers; C J H Gerrits; J H M Schellens; A S T Planting; M E L van der Burg; V van Beurden; MM de Boer-Dennert; M Harteveld; Walter J Loos; IR Hudson; Gerrit Stoter; Jaap Verweij
Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(9):2540-5.
1996: Ronald de Wit; Jos H Beijnen; Olaf van Tellingen; J H M Schellens; MM de Boer-Dennert; Jaap Verweij
Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets.
British journal of cancer 1996;74(2):323-6.
1996: J H M Schellens; J Ma; A S T Planting; M E L van der Burg; E van Meerten; MM de Boer-Dennert; P I M Schmitz; Gerrit Stoter; Jaap Verweij
Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.
British journal of cancer 1996;73(12):1569-75.
1996: J H M Schellens; Geert-Jan Creemers; Jos H Beijnen; Hilde Rosing; MM de Boer-Dennert; M McDonald; B Davies; Jaap Verweij
Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
British journal of cancer 1996;73(10):1268-71.
1996: A S T Planting; M E L van der Burg; Martin J van den Bent; MM de Boer-Dennert; Gerrit Stoter; J Verweij
Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer.
British journal of cancer 1996;73(10):1265-7.
1996: C J H Gerrits; Geert-Jan Creemers; J H M Schellens; Paul Wissel; A S T Planting; R Kunka; K Selinger; MM de Boer-Dennert; Y Marijnen; M Harteveld; Jaap Verweij
Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.
British journal of cancer 1996;73(6):744-50.
1996: Ronald de Wit; P I M Schmitz; Jaap Verweij; MM de Boer-Dennert; P H M De Mulder; A S T Planting; M E L van der Burg; Gerrit Stoter
Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(2):644-51.
1996: LJ van Warmerdam; Geert-Jan Creemers; Sjoerd Rodenhuis; Hilde Rosing; MM de Boer-Dennert; J H M Schellens; Wim W ten Bokkel Huinink; brian e davies; R A Maes; Jaap Verweij; Jos H Beijnen
Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure.
Cancer chemotherapy and pharmacology 1996;38(3):254-60.
1996: J Ma; Jaap Verweij; A S T Planting; HJ Kolker; Walter J Loos; MM de Boer-Dennert; M E L van der Burg; Gerrit Stoter; J H M Schellens
Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes.
Cancer chemotherapy and pharmacology 1996;37(4):382-4.
1995: A S T Planting; M E L van der Burg; Swan Hoo Goey; J H M Schellens; Martin J van den Bent; MM de Boer-Dennert; G Stoter; J Verweij
Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(6):613-5.
1995: J Ma; Jaap Verweij; A S T Planting; MM de Boer-Dennert; H E van Ingen; M E L van der Burg; G Stoter; J H M Schellens
Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.
British journal of cancer 1995;71(3):512-7.
1995: A S T Planting; M E L van der Burg; MM de Boer-Dennert; G Stoter; Jaap Verweij
Phase I study of weekly high-dose cisplatin combined with long-term oral etoposide in advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(2):190-2.
1995: LJ van Warmerdam; Jaap Verweij; J H M Schellens; Hilde Rosing; brian e davies; MM de Boer-Dennert; R A Maes; Jos H Beijnen
Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks.
Cancer chemotherapy and pharmacology 1995;35(3):237-45.
1994: J H M Schellens; A S T Planting; B A van Acker; Walter J Loos; MM de Boer-Dennert; M E L van der Burg; I Koier; R T Krediet; G Stoter; Jaap Verweij
Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09.
Journal of the National Cancer Institute 1994;86(12):906-12.
1994: A S T Planting; J H M Schellens; Swan Hoo Goey; M E L van der Burg; MM de Boer-Dennert; G Stoter; Jaap Verweij
Weekly high-dose cisplatin in malignant pleural mesothelioma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(4):373-4.
1993: A S T Planting; M E L van der Burg; MM de Boer-Dennert; G Stoter; Jaap Verweij
Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours.
British journal of cancer 1993;68(4):789-92.
1993: Jaap Verweij; B Lund; Jos H Beijnen; A S T Planting; MM de Boer-Dennert; I Koier; Hilde Rosing; H Hansen
Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(8):673-8.